Immutep
- Short interest
- 1.23%
- −0.89 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 18.1M
- Shares on issue
- 1.474B
Immutep (IMM) Short Interest
Immutep (ASX:IMM) had 1.23% of shares reported as short positions as of 8 Oct 2026, representing 18,085,244 shares. Immutep operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Immutep
Immutep is a biotechnology company focused on developing LAG-3 related immunotherapy products for the treatment of cancer and autoimmune diseases. The company is pioneering the LAG-3 space and has clinical-stage assets targeting areas of high unmet need.
Company profile →Immutep (ASX:IMM) has 1.23% of its shares on issue reported as short positions as of 8 Oct 2026, or about 18,085,244 shares. Over the past 30 days that figure has fallen 0.89 percentage points, and over 90 days it has fallen 1.16 percentage points. Its highest recorded short interest was 3.74% in July 2026. IMM is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads IMM today
- Zanger BreakoutWatchScore 32rank 540 of 1942
- CAN SLIMWatchScore 17rank 790 of 1541
- Minervini Trend TemplateWatchScore 7rank 1553 of 1716
- Crowded-Short BreakoutWatchScore 7rank 1408 of 1502
- Quality compoundersWatchScore 17rank 888 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
IMM fundamentals
In the year to 30 Jun 2026, Immutep (ASX:IMM) recorded revenue of A$14.6M and a net loss after tax of A$79.3M. A year earlier it recorded revenue of A$60.1K and a net loss after tax of A$61.4M. Net margin −543.3% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest IMM news
All news- Immutep & Monash Secure Further ARC Funding for LAG-3
asx · 13 Oct 2026
- Immutep Regains Compliance with Nasdaq
asx · 12 Oct 2026
- Audit and Risk Committee Update
asx · 8 Oct 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss IMM
Start a research thread or post the first pulse update